San Diego-based Acadia Pharmaceuticals Inc. appointed Stephen Davis as executive vice president, chief financial officer and chief business officer, effective immediately, the company announced.

Davis brings more than 20 years of executive-level experience in the pharmaceutical industry. He most recently was executive vice president and chief operating officer at Heron Therapeutics Inc., which he joined in 2013, Acadia (Nasdaq: ACAD) said. Previous to that, Davis was executive vice president and chief operating officer at Ardea Biosciences Inc. from 2010 to 2013, where he oversaw business functions, including finance, commercial planning and corporate development. Prior to joining Ardea, Davis served in numerous C-level roles at Neurogen Corp. from 1994 to 2010. Also, Davis is on the board at Heron Therapeutics and Synageva BioPharma Corp., according to Acadia.

“Steve’s impressive background and demonstrated leadership skills will be key as we continue to build the corporate infrastructure necessary to support the planned launch of pimavanserin in Parkinson’s disease psychosis and seek to maximize the significant opportunities ahead for pimavanserin,” said Uli Hacksell, CEO of Acadia.

Pimavanserin is the company’s lead drug candidate.

In March, Acadia announced plans to raise $182 million in a secondary stock offering.

Acadia is a biopharmaceutical company focused on developing and commercializing innovative medicines that address unmet medical needs in neurological and related central nervous system disorders.